IDEAS home Printed from https://ideas.repec.org/p/ern/wpaper/0-2003.html
   My bibliography  Save this paper

Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato

Author

Listed:
  • Gianluca Baio

    (Department of Statistical Sciences, University College London)

  • Laura Magazzini

    (Department of Economics, University of Verona)

  • Antonio Nicita

    (Department of Economics and Law, University La Sapienza Rome)

  • Fabio Pammolli

    (Politecnico di Milano and CERM Foundation - Competitività, Regole, Mercati)

  • Massimo Riccaboni

    (IMT Lucca Institute for Advanced Studies and Department of Managerial Economics, Strategy and Innovation, K.U. Leuven)

Abstract

Il presente rapporto analizza l'impatto del DL 15/04/2002 n. 63 del Governo Italiano ("Misure per il contenimento della spesa farmaceutica"), con particolare riferimento agli effetti indotti da tali misure sulle decisioni di investimento delle imprese, sulla struttura dell'industria di riferimento e sulle dinamiche di mercato che da tali misure possono discendere.

Suggested Citation

  • Gianluca Baio & Laura Magazzini & Antonio Nicita & Fabio Pammolli & Massimo Riccaboni, 2003. "Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato," Working Papers CERM 0-2003, Competitività, Regole, Mercati (CERM).
    • Handle: RePEc:ern:wpaper:0-2003
    as

    Download full text from publisher

    File URL: https://fondazionecerm.it/wp-content/uploads/wp/wpcerm-2003-00.pdf
    File Function: First version, 2003
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Avinash Dixit & Robert S. Pindyck & Sigbjorn Sodal, 1997. "A Markup Interpretation of Optimal Rules for Irreversible Investment," NBER Working Papers 5971, National Bureau of Economic Research, Inc.
    2. Bottazzi, Giulio & Dosi, Giovanni & Lippi, Marco & Pammolli, Fabio & Riccaboni, Massimo, 2001. "Innovation and corporate growth in the evolution of the drug industry," International Journal of Industrial Organization, Elsevier, vol. 19(7), pages 1161-1187, July.
    3. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
    4. R. G. D. Allen, 1975. "Index Numbers in Theory and Practice," Palgrave Macmillan Books, Palgrave Macmillan, number 978-1-349-02312-7, December.
    5. repec:bla:jindec:v:47:y:1999:i:2:p:169-94 is not listed on IDEAS
    6. Ernst R. Berndt & David M. Cutler & Richard Frank & Zvi Griliches & Joseph P. Newhouse & Jack E. Triplett, 2001. "Price Indexes for Medical Care Goods and Services -- An Overview of Measurement Issues," NBER Chapters, in: Medical Care Output and Productivity, pages 141-200, National Bureau of Economic Research, Inc.
    7. Stephane Jacobzone, 2000. "Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals," OECD Labour Market and Social Policy Occasional Papers 40, OECD Publishing.
    8. Fabio Pammolli & Laura Magazzini & Luigi Orsenigo, 2002. "The intensity of competition after patent expiry in pharmaceuticals. A cross-country analysis," Revue d'Économie Industrielle, Programme National Persée, vol. 99(1), pages 107-131.
    9. Productivity Commission, 2001. "International pharmaceutical price differences," Others 0107004, University Library of Munich, Germany.
    10. Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
    11. Berndt, Ernst R., 2000. "International comparisons of pharmaceutical prices: what do we know, and what does it mean?," Journal of Health Economics, Elsevier, vol. 19(2), pages 283-287, March.
    12. Catherine Matraves, 1999. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 47(2), pages 169-194, June.
    13. Catherine Matraves, 1998. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," CIG Working Papers FS IV 98-17, Wissenschaftszentrum Berlin (WZB), Research Unit: Competition and Innovation (CIG).
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2004. "Dynamic competition in pharmaceuticals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 175-182, May.
    2. Magazzini, Laura & Pammolli, Fabio & Riccaboni, Massimo, 2004. "Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure," MPRA Paper 15968, University Library of Munich, Germany.
    3. Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
    4. Frank Windmeijer & Eric de Laat & Rudy Douven & Esther Mot, 2006. "Pharmaceutical promotion and GP prescription behaviour," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 5-18, January.
    5. Chiara Bonassi & Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2007. "Regolazione, innovazione e ciclo di vita dei prodotti - per una riforma del pricing al lancio e della governance della spesa nella farmaceutica pubblica," Working Papers CERM 02-2007, Competitività, Regole, Mercati (CERM).
    6. Herrmann, Andrea M., 2008. "Choosing and successfully sustaining competitive strategies in the European pharmaceutical industry," MPIfG Discussion Paper 08/9, Max Planck Institute for the Study of Societies.
    7. Herrmann, Andrea M., 2008. "On the discrepancies between macro and micro level identification of competitive strategies," MPIfG Discussion Paper 08/6, Max Planck Institute for the Study of Societies.
    8. Herrmann, Andrea M. & Peine, Alexander, 2011. "When 'national innovation system' meet 'varieties of capitalism' arguments on labour qualifications: On the skill types and scientific knowledge needed for radical and incremental product innovations," Research Policy, Elsevier, vol. 40(5), pages 687-701, June.
    9. Ramesh Govindaraj & Gnanaraj Chellaraj, 2002. "The Indian Pharmaceutical Sector : Issues and Options for Health Sector Reform," World Bank Publications - Books, The World Bank Group, number 15231.
    10. Morgan, Steve & McMahon, Meghan & Greyson, Devon, 2008. "Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia," Health Policy, Elsevier, vol. 87(2), pages 133-145, August.
    11. Antonio Cabrales, 2003. "Pharmaceutical generics, vertical product differentiation and public policy," Economics Working Papers 662, Department of Economics and Business, Universitat Pompeu Fabra.
    12. Ammas Siraj Mohammed & Nigist Alemayehu Woldekidan & Fuad Adem Mohammed, 2020. "Knowledge, attitude, and practice of pharmacy professionals on generic medicines in Eastern Ethiopia: A cross-sectional study," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-12, July.
    13. Catherine Matraves & Laura Rondi, 2007. "Product Differentiation, Industry Concentration and Market Share Turbulence," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 14(1), pages 37-57.
    14. Pedro L. Marín & Georges Siotis, 2007. "Innovation And Market Structure: An Empirical Evaluation Of The ‘Bounds Approach’ In The Chemical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 55(1), pages 93-111, March.
    15. Laura Magazzini & Fabio Pammolli & Gianluca Papa & Nicola Carmine Salerno, 2005. "Generici vs. Branded: confronto internazionale su prodotti off-patent rimborsati dal SSN," Working Papers CERM 01-2005, Competitività, Regole, Mercati (CERM).
    16. Thompson, Simon G. & Nixon, Richard M. & Grieve, Richard, 2006. "Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study," Journal of Health Economics, Elsevier, vol. 25(6), pages 1015-1028, November.
    17. Aysegul Timur & Gabriel Picone & Jeffrey DeSimone, 2011. "Has the European union achieved a single pharmaceutical market?," International Journal of Health Economics and Management, Springer, vol. 11(4), pages 223-244, December.
    18. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
    19. Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2013. "Technological Regimes and Demand Structure in the Evolution of the Pharmaceutical Industry," Economic Complexity and Evolution, in: Andreas Pyka & Esben Sloth Andersen (ed.), Long Term Economic Development, edition 127, pages 61-94, Springer.
    20. Antonio Cabrales & Sergi Jiménez‐Martín, 2013. "The Determinants Of Pricing In Pharmaceuticals: Are Us Prices Really So High?," Health Economics, John Wiley & Sons, Ltd., vol. 22(11), pages 1377-1397, November.

    More about this item

    Keywords

    spesa farmaceutica; industria farmacuetica;

    JEL classification:

    • D40 - Microeconomics - - Market Structure, Pricing, and Design - - - General
    • H50 - Public Economics - - National Government Expenditures and Related Policies - - - General
    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
    • H70 - Public Economics - - State and Local Government; Intergovernmental Relations - - - General
    • H75 - Public Economics - - State and Local Government; Intergovernmental Relations - - - State and Local Government: Health, Education, and Welfare
    • H77 - Public Economics - - State and Local Government; Intergovernmental Relations - - - Intergovernmental Relations; Federalism
    • I00 - Health, Education, and Welfare - - General - - - General
    • I10 - Health, Education, and Welfare - - Health - - - General
    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:0-2003. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Guido Bora` (email available below). General contact details of provider: https://edirc.repec.org/data/cermmit.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.